Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Adalimumab in Moderate to Severe Hidradenitis Suppurativa
2011-003400-20Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in hidradenitis suppurativa (HS) comparing Adalimumab with Placebo (2 arms). Primary endpoint: HiSCR response at Week 12. Started Dec 2011; status: completed.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2011-003400-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003400-20.